Back to Directory

Maggie Albano

Email

malbano@fhi360.org

Phone

202-464-3753

Institution

FHI 360

Address

IMPAACT Operations Center
FHI 360
359 Blackwell Street
Suite 200
Durham, NC 27701
USA

Request an Update

Affiliated Studies

IMPAACT 2046: UPLIFT Study

DAIDS Number

Research Area

Brain and Mental Health

Study Status

IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV

DAIDS Number

Research Area

Study Status

Open to Accrual

IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

DAIDS Number

Research Area

Cure and Immunotherapy

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum.

DAIDS Number

Research Area

Study Status

Closed to Follow Up

Show All